Naglazyme
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis VI
Conditions
Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome
Trial Timeline
May 1, 2006 → Apr 1, 2009
NCT ID
NCT00299000About Naglazyme
Naglazyme is a approved stage product being developed by BioMarin Pharmaceutical for Mucopolysaccharidosis VI. The current trial status is completed. This product is registered under clinical trial identifier NCT00299000. Target conditions include Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00299000 | Approved | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis VI